IBC Collaboration Leads to $550,000 for IBC, Breast Cancer and More
WEST LAFAYETTE – June 2017
Inflammatory Breast Cancer Research Foundation, Milburn Foundation and Susan G. Komen®, are excited to share that nearly $550,000 has been raised to fund research into inflammatory breast cancer (IBC) as well as other critical breast cancer research and community health programs. As you know, IBC is a less common but very aggressive form of breast cancer.
Throughout the month of March, Milburn and the Inflammatory Breast Cancer Research Foundation teamed up to match all donations made to Komen up to a predetermined goal of $50,000–a campaign which ultimately raised more than half a million dollars, and exceeded the goal ten-fold. In total, nearly $550,000 was raised through the campaign which will support, in part, research aimed at finding new ways of detecting and treating IBC. IBC awareness was also accomplished with IBC-centric materials, associated with the campaign, going out to over 920,000 individuals in Komen’s network.
This marks the second time the three organizations have partnered to advance IBC research as a team. Last fall, the partners announced two funding opportunities for investigators with novel ideas about diagnosis and treatment of IBC. This project alone drove more awareness of IBC within the research community and garnered significantly more submissions than were originally anticipated. We’re now ready to announce the recipients of these awards.
John Martens, Ph.D., from Erasmus Universitair Medisch Centrum Rotterdam, who received funding to combine patient information from an established Dutch IBC registry with the latest genomic technology to improve the diagnosis, monitoring, and treatment of IBC.
Mihaela Skobe, Ph.D., from the Icahn School of Medicine at Mount Sinai also received funding to understand how the interactions between Triple Negative IBC and the lymphatic system influence the aggressiveness of the disease, ultimately providing insight on potential new treatment strategies.
“Research progress in a disease like IBC, requires vision, creative thinking and action. Through the collaborative IBC research grants and the recent matching gift campaign we’re developing a new model for meeting the needs of those facing an IBC diagnosis,” said Ginny Mason, RN, BSN, Executive Director of the IBC Research Foundation.
“The success of this partnership proves that strategic partnerships spanning across multiple charities can yield powerful results for specialized research,” said Bryon Davis, President of the Milburn Foundation. “This partnership was actively designed and facilitated for results, requiring all parties to look at challenges in new ways and leveraging each organization’s strengths.”
“Our partnership has already allowed us to fund important research, and will go a long way toward helping to reduce deaths from breast cancer,” said Ellen Willmott, interim President and CEO for Susan G. Komen. “Komen has set a Bold Goal, but we know we will not be able to achieve this alone – only as a community, which is why our partnership with the Milburn Foundation and the Inflammatory Breast Cancer Research Foundation is so valuable.”
A portion of the funds from the March campaign will be used to provide additional research support to the most promising of the two recipients named above, following a review of their progress to date and other prerequisites.
About IBC Research Foundation
Since 1999 the Inflammatory Breast Cancer Research Foundation (IBCRF) has been leading the way in improving the lives of those touched by inflammatory breast cancer (IBC) through the power of action and advocacy. This is accomplished by tenaciously fostering innovative research, creatively educating stakeholders, and tirelessly advocating for both current IBC patients and survivors.
As a web-based non-profit, IBCRF relies on its dedicated volunteers across the country. Guided by the Medical Advisory Board, a group of extraordinary oncology professionals, IBCRF has funded patient-focused IBC research resulting in new discoveries as well as clinical trials. Learn more at www.ibcresearch.org or call 1-877-stop ibc. On social media? Join us on Facebook and Twitter (@IBCResearch)
About The Milburn Foundation
The Milburn Foundation is a private charity that actively structures creative partnerships with corporations and other charities to drive philanthropic innovation for targeted causes like breast cancer. Large or small companies interested in inventive Corporate Social Responsibility (CSR) solutions may have an opportunity to double or triple their impact through Milburn Foundation programs. The Milburn Foundation is the proud recipient of the 2016 Susan G. Komen Reach Award (for fundraising innovation) and the Milburn Foundation is delighted to join the ranks of Conde Nast and other notable organizations who previously won this award. Find out more by visiting TheMilburnFoundation.org.
About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization, funding more breast cancer research than any other nonprofit outside of the federal government while providing real-time help to those facing the disease. Komen has set a Bold Goal to reduce the current number of breast cancer deaths by 50 percent in the U.S. by 2026. Since its founding in 1982, Komen has funded more than $920 million in research and provided more than $2 billion in funding to screening, education, treatment and psychosocial support programs serving millions of people in more than 30 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. That promise has become Komen’s promise to all people facing breast cancer. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social
Inflammatory Breast Cancer Research Foundation, Milburn Foundation and Susan G. Komen® Push For Breadkthroughs in IBC Research
West Lafayette – October 18, 2016 –
Inflammatory Breast Cancer Research Foundation and two prestigious foundations today announced a collaboration aimed at finding new approaches to diagnosing and treating inflammatory breast cancer (IBC). Inflammatory Breast Cancer Research Foundation, the Milburn Foundation and Susan G. Komen are seeking applications that will explore new ideas and novel approaches to combating IBC– a less common but particularly aggressive form of breast cancer that is difficult to diagnose and treat.
IBC is often difficult to diagnose because it frequently does not present as a lump. Instead, women notice symptoms such as redness and swelling or enlargement of the breast that are often mistaken as an infection, delaying diagnosis. By the time IBC is diagnosed, it is at an advanced stage (i.e., stage III or stage IV).
“It’s been a challenge to bring adequate research attention to inflammatory breast cancer,” said Ginny Mason RN, IBC Survivor and Executive Director of Inflammatory Breast Cancer Research Foundation. “Collaboration is essential for patient-focused success in both the research and nonprofit communities. We’re excited to be a part of this multi-organization initiative that provides a platform for creative collaborations and encourages submissions across disciplines.”
President and Chief Investment Officer of the Milburn Foundation Bryon Davis shared his thoughts on the genesis of collaboration among the three organizations.
“The Milburn Foundation is very pleased to have provided a valuable voice in structuring this multiparty collaboration,” Davis said. “By providing funding support and fostering relationships we helped to facilitate a new alliance that will support research innovation. We are exceptionally proud of what this initiative represents and are honored to partner with two organizations that demonstrate such a sincere commitment to the breast cancer cause.”
“Additional IBC research is needed to improve diagnosis of this unique subtype of breast cancer and understand how biology drives its progression, thereby leading to improved prognosis and more-effective treatment for those with IBC,” said Komen President and CEO Dr. Judy Salerno .
The Request for Applications for the two grants, each for $60,000, is now open on komen.org. Applications will be accepted through November 28, 2016.
About Inflammatory Breast Cancer Research Foundation
Inflammatory Breast Cancer Research Foundation was formed in 1999 with the goal of facilitating research and educating both the lay and medical communities about IBC. As a web-based, focused non-profit, IBC Research Foundation has funded significant, quality IBC research projects under the guidance of a stellar Medical Advisory Board. IBC educational information can be found on the Foundation website and through the monthly newsletter. Survivor volunteers provide individual support by phone and email. The IBC Research Foundation strives to improve the lives of those touched by IBC through research, creatively educating stakeholders of all kinds, and tirelessly advocating for both current IBC patients and survivors. To learn more visit: www.ibcresearch.org or call 1-877-stop ibc. Find us on Facebook and Twitter (@IBCResearch).
About The Milburn Foundation
The Milburn Foundation is a catalyst for building momentum behind critical breast cancer research and is also the proud recipient of the 2016 Susan G. Komen Reach Award for fundraising innovation (see March Madness in the Breast Cancer Arena). We have an established history of high dollar donations to both Susan G. Komen and the IBC Research Foundation. We partner with companies and non-profits to increase their impact through matching gift and creative programs. As a private foundation we are poised to play a unique role in structuring partnerships and fund raising programs. Find out more by visiting TheMilburnFoundation.org.
About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization outside of the federal government, funding more breast cancer research than any other nonprofit while providing real-time help to those facing the disease. Since its founding in 1982, Komen has funded more than $920 million in research and provided more than $2 billion in funding to screening, education, treatment and psychosocial support programs. Komen has worked in more than 60 countries worldwide. Komen was founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy’s life. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social
You Don’t Have to Have a Lump to Have Breast Cancer
The Inflammatory Breast Cancer Research Foundation is dedicated to researching the cause of Inflammatory Breast Cancer (IBC), an advanced and accelerated form of breast cancer usually not detected by mammograms or ultrasounds. IBC can be diffuse throughout the breast with no palpable mass. Lymph node involvement is assumed. Inflammatory breast cancer requires immediate aggressive treatment with chemotherapy prior to surgery and is treated differently than other types of breast cancer.
What is Inflammatory Breast Cancer?
“Inflammatory breast cancer is a rare and very aggressive disease in which cancer cells block lymph vessels in the skin of the breast. This type of breast cancer is called “inflammatory” because the breast often looks swollen and red, or “inflamed.”
Inflammatory breast cancer accounts for 1 to 5 percent of all breast cancers diagnosed in the United States. Most inflammatory breast cancers are invasive ductal carcinomas, which means they developed from cells that line the milk ducts of the breast and then spread beyond the ducts.
Inflammatory breast cancer progresses rapidly, often in a matter of weeks or months. Inflammatory breast cancer is either stage III or IV at diagnosis, depending on whether cancer cells have spread only to nearby lymph nodes or to other tissues as well.
Additional features of inflammatory breast cancer include the following:
- Compared with other types of breast cancer, inflammatory breast cancer tends to be diagnosed at younger ages (median age of 57 years, compared with a median age of 62 years for other types of breast cancer).
- It is more common and diagnosed at younger ages in African American women than in white women. The median age at diagnosis in African American women is 54 years, compared with a median age of 58 years in white women.
- Inflammatory breast tumors are frequently hormone receptor negative, which means that hormone therapies, such as tamoxifen, that interfere with the growth of cancer cells fueled by estrogen may not be effective against these tumors.
- Inflammatory breast cancer is more common in obese women than in women of normal weight.
Like other types of breast cancer, inflammatory breast cancer can occur in men, but usually at an older age (median age at diagnosis of 66.5 years) than in women.”*
*Citation: “Inflammatory Breast Cancer Questions and Answers Sheet.” National Cancer Institute at the National Institutes of Health. www.cancer.gov, 2012. Retrieved from Web 17 May 2012. http://www.cancer.gov/cancertopics/factsheet/Sites-Types/IBC.